Replies to post #27902 on Biotech Values

[DewDiligence]

>Dew – IDIX – I thought that one of the primary unknowns back in March was the question that lower dosages of the drug could be effective.<

The March 24 CC covered this in a lot of detail and it was made clear then that 200mg worked almost as well as 800mg in the treatment-naïve phase-2b trial. The main difference in efficacy between 200mg and 800mg was the speed with which viral load was reduced rather than the extent to which viral load was reduced.

Hence, IDIX’s PR this weekend is for the most post just a confirmation of what was disclosed orally in March.